| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 06/22/2006 | US20060134119 Drugs containing galectin 9 |
| 06/22/2006 | US20060134117 Preventives/remedies for cancer |
| 06/22/2006 | US20060134113 Preventive or therapeutic agent for sensitized T cell-mediated diseases comprising IL-6 antagonist as an active ingredient |
| 06/22/2006 | US20060134112 Uses of mammalian cytokine; related reagents |
| 06/22/2006 | US20060134109 G protein coupled receptors and uses thereof |
| 06/22/2006 | US20060134103 Compounds and molecular complexes comprising multiple binding regions directed to transcytotic ligands |
| 06/22/2006 | US20060134100 Dc-sign blockers and their use for preventing or treating viral infections |
| 06/22/2006 | US20060134094 Fibrin material and method for producing and using the same |
| 06/22/2006 | US20060134093 Fibrin cell supports and methods of use thereof |
| 06/22/2006 | US20060134092 Method of degrading hardly degradable protein |
| 06/22/2006 | US20060134091 Additive for an animal feed |
| 06/22/2006 | US20060134090 Method and dietary composition for improving lipid digestibility |
| 06/22/2006 | US20060134089 Nitric oxide synthase gene transfer to the atrium for vagal tone increase |
| 06/22/2006 | US20060134088 Enzymatic treatment of retinitis pigmentosa and relevant pharmaceutical composition therefor in form of a kit |
| 06/22/2006 | US20060134087 ITI-D1 Kunitz domain mutants as hNE inhibitors |
| 06/22/2006 | US20060134086 Targeted enzymes |
| 06/22/2006 | US20060134085 Compositions containing coenzyme q10 |
| 06/22/2006 | US20060134083 Compositions comprising sclareol or derivatives thereof and uses thereof |
| 06/22/2006 | US20060134081 Use of marrow-derived glial progenitor cells as gene delivery vehicles into the central nervous system |
| 06/22/2006 | US20060134079 Implantable medical devices comprising isolated extracellular matrix |
| 06/22/2006 | US20060134075 Composition and method for improving function of embryonic kidney transplants |
| 06/22/2006 | US20060134072 Self-assembling protein matrix prepared from natural extracellular matrices |
| 06/22/2006 | US20060134064 Combined treatment with interferon-alpha and an epidermal growth factor receptor kinase inhibitor |
| 06/22/2006 | US20060134063 Agents for proliferating pancreatic beta-cells of the islets of langerhans, agents for suppressing apoptosis of said cells, and screening of candidate compounds for these agents |
| 06/22/2006 | US20060134061 Bisacyloxypropylcysteine conjugates and the use thereof |
| 06/22/2006 | DE102004060319A1 Preparation of peptidoglycan, used e.g. to stabilize emulsions, from gram-positive bacteria comprises incubating bacteria containing biomass at defined temperature to form a mixture with e.g. solvents, soluble components and peptidoglycan |
| 06/22/2006 | CA2836267A1 Pancreatic polypeptide family motifs, polypeptides and methods comprising the same |
| 06/22/2006 | CA2767026A1 Protein formulation for administering an active enamel substance |
| 06/22/2006 | CA2634589A1 Irreversibly-inactivated pepsinogen fragment and pharmaceutical compositions comprising this fragment for detecting, preventing, and treating hiv |
| 06/22/2006 | CA2633435A1 Antimicrobial peptides and methods of use |
| 06/22/2006 | CA2592343A1 Metabolites of cyclosporin analogs |
| 06/22/2006 | CA2591659A1 Regulation of metalloprotease cleavage of cell surface proteins |
| 06/22/2006 | CA2591587A1 Methods for treating autoimmune disorders |
| 06/22/2006 | CA2591443A1 Method to enhance the bone formation activity of bmp by runx2 acetylation |
| 06/22/2006 | CA2591087A1 Method for treatment of hiv infection |
| 06/22/2006 | CA2591035A1 Novel multimeric cd40 ligands, method for preparing same and use thereof for preparing drugs |
| 06/22/2006 | CA2590675A1 Nanoparticulate tacrolimus formulations |
| 06/22/2006 | CA2590369A1 Compositions comprising sclareol or derivatives thereof and uses thereof |
| 06/22/2006 | CA2590095A1 Compositions comprising oncostatin m for enhancing keratinocyte migration and epidermal repair |
| 06/22/2006 | CA2589975A1 Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| 06/22/2006 | CA2589889A1 Therapeutic formulations of keratinocyte growth factor |
| 06/22/2006 | CA2589670A1 Compositions for preventing, reducing or treating keratinocyte-mediated inflammation |
| 06/22/2006 | CA2589553A1 Use of flagellin in the immunotherapy of yersinia pestis |
| 06/22/2006 | CA2589498A1 Treatment of hepatitis c in the asian population with interferon-beta |
| 06/22/2006 | CA2588594A1 Pancreatic polypeptide family motifs, polypeptides and methods comprising the same |
| 06/22/2006 | CA2587932A1 Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy |
| 06/22/2006 | CA2587285A1 Actinomadura chromoprotein, apoprotein, and gene cluster |
| 06/22/2006 | CA2587209A1 Osteoprotegerin variant proteins |
| 06/22/2006 | CA2587136A1 Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens |
| 06/22/2006 | CA2587081A1 Compositions for treatment of ear infections |
| 06/21/2006 | EP1671981A2 Nucleic acids and proteins from streptococcus group A |
| 06/21/2006 | EP1671654A2 Conjugates of hydroxyalkyl starch and an active agent |
| 06/21/2006 | EP1671644A2 Pharmaceutical compositions containing Lysostaphin alone or in combination with an antibiiotic for the treatment of Staphylococcal infections |
| 06/21/2006 | EP1671643A1 Medicinal composition for treating chronic hepatitis c |
| 06/21/2006 | EP1671642A1 Compositions comprising (ant)agonists of oncostatin M (OSM), IL-31 and IFN-gamma for modulating keratinocyte migration and functions via a receptor containing OSMRbeta as a subunit, and applications thereof. |
| 06/21/2006 | EP1671641A1 Remedy and therapeutic method for periodontal diseases and pulpal diseases |
| 06/21/2006 | EP1671640A1 Mutant strain of Actinoplanes teichomyceticus for the production of teicoplanin |
| 06/21/2006 | EP1671632A1 Pharmaceutical combination of angiotensin II antagonists and ACE inhibitors |
| 06/21/2006 | EP1671126A2 Diagnosis and treatment of mycobacterial infections |
| 06/21/2006 | EP1671116A2 Novel antisense oligomers and use thereof |
| 06/21/2006 | EP1671097A2 Methods and compositions for producing secreted trimeric receptor analogs and biologically active fusion proteins |
| 06/21/2006 | EP1670931A2 Method for the production of fusion proteins in transgenic mammal milk |
| 06/21/2006 | EP1670926A2 Modified cea /b7 vector |
| 06/21/2006 | EP1670923A1 Method for mass production of human follicle stimulating hormone |
| 06/21/2006 | EP1670919A2 Method for the production of a cell and/or tissue and/or disease phase specific medicament |
| 06/21/2006 | EP1670908A2 Medical use of tbk-1 or of inhibitors thereof |
| 06/21/2006 | EP1670899A2 Vaccines for cancer, autoimmune disease and infections |
| 06/21/2006 | EP1670820A2 Antigens for an east coast fever vaccine |
| 06/21/2006 | EP1670819A1 A novel conotoxin modulating sodium channels |
| 06/21/2006 | EP1670815A2 Melanocortin receptor agonists |
| 06/21/2006 | EP1670814A1 Amidomethyl substituted 1-(carboxyalkyl)-cyclopentylcarbonylamino-benzazepine-n-acetic acid derivatives, process and intermediate products for their preparation and medicaments containing these compounds |
| 06/21/2006 | EP1670514A2 Antitumor agent comprising a histone deacetylase inhibitor and a topoisomerase ii inhibitor |
| 06/21/2006 | EP1670511A2 Cripto antagonism of activin and tgf-b signaling |
| 06/21/2006 | EP1670502A2 Oligopeptides as coating material for medical products |
| 06/21/2006 | EP1670501A2 Methods of treating autoimmune diseases using il-21 |
| 06/21/2006 | EP1670499A2 Methods for treating cardiovascular disease using a soluble ctla4 molecule |
| 06/21/2006 | EP1670498A1 p185 neu -ENCODING DNA AND THERAPEUTICAL USES THEREOF |
| 06/21/2006 | EP1670497A1 METHODS FOR IDENTIFYING MODULATORS OF PROTEIN KINASE C-EPSILON (PKCϵ) AND METHOD OF TREATMENT OF ABERRANT GLUCOSE METABOLISM ASSOCIATED THEREWITH |
| 06/21/2006 | EP1670496A1 A teicoplanin composition with improved antibiotic activity |
| 06/21/2006 | EP1670495A1 Stabilization of pharmaceutical protein formulations with small peptides |
| 06/21/2006 | EP1670494A1 Glatiramer acetate for use as an immuno-modulatory agent |
| 06/21/2006 | EP1670493A2 In vitro development of tissues and organs |
| 06/21/2006 | EP1670492A2 Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions |
| 06/21/2006 | EP1670490A1 Method for inhibiting bacterial colonisation |
| 06/21/2006 | EP1670465A1 Ocular solutions containing a macrolide antibiotic and/or mycophenolic acid |
| 06/21/2006 | EP1670462A1 Combination therapy for hcv infection |
| 06/21/2006 | EP1670449A2 Thyroid hormone analogs and methods of use in angiogenesis |
| 06/21/2006 | EP1670439A2 Solid dosage form comprising desmopressin |
| 06/21/2006 | EP1670434A1 Methods for preparing oil bodies comprising active ingredients |
| 06/21/2006 | EP1670427A2 Methods and reagents for the treatment of immunoinflammatory disorders |
| 06/21/2006 | EP1670417A2 Compositions of a cyclooxygenase-2 selective inhibitor administered under hypothermic conditions for the treatment of ischenic mediated central nervous system disorders or injury |
| 06/21/2006 | EP1670415A2 Animal model for protease activity and liver damage |
| 06/21/2006 | EP1670413A2 Method of reducing visceral fat by increasing levels of insulin-like growth factor-i (igf-i) |
| 06/21/2006 | EP1545590B1 Enzymatic treatment of retinitis pigmentosa and relevant pharmaceutical composition in form of a kit |
| 06/21/2006 | EP1536822B1 Stable pharmaceutical composition comprising erythropoietin |
| 06/21/2006 | EP1482968B1 Treatment of type i diabetes mellitus using growth hormone antagonist |
| 06/21/2006 | EP1463504B1 Compositions comprising epothilones and their use for the treatment of the carcinoid syndrome |
| 06/21/2006 | EP1420646B1 Antimicrobial agent |
| 06/21/2006 | EP1385989A4 Il-1 inhibition for myeloma and related disorders |
| 06/21/2006 | EP1365766B1 Pharmaceutical composition for treatment of phimosis using topical corticosteroid |